Adhesions are not preventable by surgical technique alone
Adhesions develop routinely following both open and laparoscopic* abdominal surgery, and have been reported at second-look surgery to occur in up to 93% of patients (n=210) following one or more open abdominal operations3.
The clinical and economic burden of adhesions is extensive
Adhesions are a major cause of small bowel obstruction, infertility, chronic pelvic pain, and complicate future surgery, with annual surgical costs of more than $2 billion in the U.S6.
SEPRAFILM efficacy in abdominal surgery
In a randomized, prospective, double-blinded, multicenter clinical study involving 183 patients [175 evaluable] with ulcerative colitis and familiar polyposis undergoing 2-stage intestinal resection, more than half of the patients treated with SEPRAFILM were adhesion-free at 12 weeks compared to 6% of control patients2.
SEPRAFILM is the only adhesion prevention product approved in the US for abdominal open procedures
SEPRAFILM efficacy in pelvic surgery
In a prospective, randomized, blinded, multicenter clinical study involving 127 patients undergoing gynecologic surgery, SEPRAFILM reduced the mean number of sites adherent to the uterine surface following myomectomy compared with untreated patients. SEPRAFILM also significantly reduced the extent and severity of adhesions in patients undergoing uterine myomectomy compared with untreated patients4.
The safety and efficacy of SEPRAFILM Adhesion Barrier has not been evaluated in clinical studies in the presence of malignancies in the abdominopelvic cavity. In patients undergoing surgery for ovarian, primary peritoneal or fallopian tube malignancies, SEPRAFILM use has been reported as having an increased risk of intra-abdominal fluid collection and/or abscess, particularly when extensive debulking surgery was required.
Additional Product Benefits
Protection When It Matters Most
Separates tissues for up to 7 days - the critical tissue healing period
A Proven Legacy
More than 4 million patients have received SEPRAFILM in clinical use worldwide. Robust clinical trials (n=2,133) across five clinical studies resulted in Seprafilm significantly reducing the incidence, extent, and severity following abdominopelvic laparotomy surgery1,5
Bioresorbable and Synthetic
SEPRAFILM is composed of sodium hyaluronate and carboxymethylcellulose (HA/CMC)
SEPRAFILM Indications and Important Safety Information
INDICATIONS FOR USE:
SEPRAFILM Adhesion Barrier is indicated for use in patients undergoing abdominal or pelvic laparotomy as an adjunct intended to reduce the incidence, extent and severity of postoperative adhesions between the abdominal wall and the under-lying viscera such as omentum, small bowel, bladder, and stomach, and between the uterus and surrounding structures such as tubes and ovaries, large bowel, and bladder.
IMPORTANT RISK INFORMATION
SEPRAFILM Adhesion Barrier is contraindicated in patients with a history of hypersensitivity to Seprafilm and/or to any component of SEPRAFILM. SEPRAFILM Adhesion Barrier is contraindicated for use wrapped directly around a fresh anastomotic suture or staple line; as such use increases the risk of anastomotic leak and related events (fistula, abscess, leak, sepsis, peritonitis). SEPRAFILM Adhesion Barrier must be used according to the instructions for use. SEPRAFILM Adhesion Barrier is for single use only, supplied sterile and must not be re-sterilized. Every opened and unused SEPRAFILM pouch must be discarded. Do not use product if pouch is damaged or opened. The number of sheets used should be just adequate to cover the under surface of the abdominal wall or uterine incision in a single layer.
In patients who have ovarian, primary peritoneal or fallopian tube malignancies, SEPRAFILM use has been reported to have an increased risk of intra-abdominal fluid collection and/or abscess, particularly when extensive debulking surgery was required.
The safety and effectiveness of SEPRAFILM Adhesion Barrier has not been evaluated in clinical studies for the following: Patients with frank infections in the abdominopelvic cavity; patients with abdominopelvic malignancy; device placement in locations other than directly beneath an abdominal wall incision following laparotomy, or directly on the uterus following open myomectomy (not laparoscopic); patients with ongoing local and/or systemic inflammatory cell responses; device use in the presence of other implants, e.g. surgical mesh; patients requiring re-operation within four weeks of SEPRAFILM placement – during anticipated time of peak adhesion formation. Foreign body reactions have occurred with SEPRAFILM Adhesion Barrier.
The safety and effectiveness of SEPRAFILM Adhesion Barrier in combination with other adhesion prevention products and/or in other surgical procedures not within the abdominopelvic cavity have not been established in clinical studies.
The safe and effective use of SEPRAFILM Adhesion Barrier in pregnancy and Cesarean section has not been evaluated. No clinical studies have been conducted in pregnant women or women who have become pregnant within the first month after exposure to SEPRAFILM Adhesion Barrier. Therefore, this product is not recommended for use during pregnancy and avoidance of conception should be considered during the first complete menstrual cycle after use of SEPRAFILM Adhesion Barrier.
Long term clinical outcomes such as chronic pain and infertility have not been determined in clinical studies.
RX Only. For safe and proper use of this device refer to the complete Instructions for Use.